Drug intelligence / Profile preview

ReRx-002

Development stage: Preclinical
Lead developer: ReRx Therapeutics

Overview

ReRx-002 is an early-stage therapeutic candidate being developed by ReRx Therapeutics for the treatment of unspecified metabolic diseases. Currently in the early discovery phase, the drug is part of a pipeline focused on metabolic modulators that target pathways involved in energy expenditure and homeostasis. While specific molecular targets and modalities for ReRx-002 have not been publicly disclosed, it follows the company's lead program, ReRx-001, which is a small molecule targeting similar metabolic pathways for obesity and related conditions.

Beyond the preview

Go deeper on ReRx-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReRx-002.

Explore the full profile